Compare FPI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | KROS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.1M | 655.9M |
| IPO Year | 2014 | 2020 |
| Metric | FPI | KROS |
|---|---|---|
| Price | $10.37 | $20.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.20 |
| AVG Volume (30 Days) | 587.3K | ★ 969.1K |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 296.76 | N/A |
| EPS | 1.27 | ★ 1.57 |
| Revenue | $52,990,000.00 | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,876.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $8.17 | $13.23 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $9.37 | $9.12 |
| 52 Week High | $12.87 | $22.55 |
| Indicator | FPI | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 71.85 | 57.16 |
| Support Level | $9.65 | $20.73 |
| Resistance Level | $10.13 | $21.75 |
| Average True Range (ATR) | 0.15 | 1.06 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 89.77 | 57.76 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.